142 related articles for article (PubMed ID: 7915910)
1. Effects of Cremophor EL on distribution of Taxol to serum lipoproteins.
Sykes E; Woodburn K; Decker D; Kessel D
Br J Cancer; 1994 Sep; 70(3):401-4. PubMed ID: 7915910
[TBL] [Abstract][Full Text] [Related]
2. Interactions of Solutol HS 15 and Cremophor EL with plasma lipoproteins.
Woodburn K; Sykes E; Kessel D
Int J Biochem Cell Biol; 1995 Jul; 27(7):693-9. PubMed ID: 7648425
[TBL] [Abstract][Full Text] [Related]
3. Interaction of cremophor EL with human plasma.
Kongshaug M; Cheng LS; Moan J; Rimington C
Int J Biochem; 1991; 23(4):473-8. PubMed ID: 2015955
[TBL] [Abstract][Full Text] [Related]
4. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
5. Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal.
Kessel D; Woodburn K; Decker D; Sykes E
Oncol Res; 1995; 7(5):207-12. PubMed ID: 8534926
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of lipoprotein fractionation from 275 or 350 microliter of serum by ultracentrifugation and polyanion-precipitation.
Widhalm K; Strobl W; Weninger M
Artery; 1980; 8(2):199-204. PubMed ID: 7458687
[No Abstract] [Full Text] [Related]
7. The alteration of plasma lipoproteins by cremophor EL.
Woodburn K; Kessel D
J Photochem Photobiol B; 1994 Mar; 22(3):197-201. PubMed ID: 8014752
[TBL] [Abstract][Full Text] [Related]
8. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.
Webster L; Linsenmeyer M; Millward M; Morton C; Bishop J; Woodcock D
J Natl Cancer Inst; 1993 Oct; 85(20):1685-90. PubMed ID: 8105099
[TBL] [Abstract][Full Text] [Related]
9. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.
Szebeni J; Muggia FM; Alving CR
J Natl Cancer Inst; 1998 Feb; 90(4):300-6. PubMed ID: 9486816
[TBL] [Abstract][Full Text] [Related]
10. Composition and electrophoretic mobility of plasma lipoproteins of dromedary camels (Camelus dromedarius).
Asadi F; Shahriari A; Asadian P; Pourkabir M; Samadaei M
Am J Vet Res; 2008 Jul; 69(7):880-5. PubMed ID: 18593238
[TBL] [Abstract][Full Text] [Related]
11. The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.
Nygren P; Csoka K; Jonsson B; Fridborg H; Bergh J; Hagberg H; Glimelius B; Brodin O; Tholander B; Kreuger A
Br J Cancer; 1995 Mar; 71(3):478-81. PubMed ID: 7880727
[TBL] [Abstract][Full Text] [Related]
12. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
van Tellingen O; Huizing MT; Panday VR; Schellens JH; Nooijen WJ; Beijnen JH
Br J Cancer; 1999 Sep; 81(2):330-5. PubMed ID: 10496361
[TBL] [Abstract][Full Text] [Related]
13. Preferential binding of chlordecone to the protein and high density lipoprotein fractions of plasma from humans and other species.
Soine PJ; Blanke RV; Guzelian PS; Schwartz CC
J Toxicol Environ Health; 1982 Jan; 9(1):107-18. PubMed ID: 6174734
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-induced cytotoxicity--the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein.
Fjällskog ML; Frii L; Bergh J
Eur J Cancer; 1994; 30A(5):687-90. PubMed ID: 7915908
[TBL] [Abstract][Full Text] [Related]
15. Cell line and schedule-dependent cytotoxicity of paclitaxel (Taxol): role of the solvent Cremophor EL/ethanol.
Cordes N; Plasswilm L
Anticancer Res; 1998; 18(3A):1851-7. PubMed ID: 9673415
[TBL] [Abstract][Full Text] [Related]
16. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL.
Theis JG; Liau-Chu M; Chan HS; Doyle J; Greenberg ML; Koren G
J Clin Oncol; 1995 Oct; 13(10):2508-16. PubMed ID: 7595701
[TBL] [Abstract][Full Text] [Related]
17. Induction of oxidative stress by Taxol® vehicle Cremophor-EL triggers production of interleukin-8 by peripheral blood mononuclear cells through the mechanism not requiring de novo synthesis of mRNA.
Ilinskaya AN; Clogston JD; McNeil SE; Dobrovolskaia MA
Nanomedicine; 2015 Nov; 11(8):1925-38. PubMed ID: 26282378
[TBL] [Abstract][Full Text] [Related]
18. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel.
Rischin D; Webster LK; Millward MJ; Linahan BM; Toner GC; Woollett AM; Morton CG; Bishop JF
J Natl Cancer Inst; 1996 Sep; 88(18):1297-301. PubMed ID: 8797769
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of anaphylactoid reactions: improper preparation of high-dose intravenous cyclosporine leads to bolus infusion of Cremophor EL and cyclosporine.
Liau-Chu M; Theis JG; Koren G
Ann Pharmacother; 1997 Nov; 31(11):1287-91. PubMed ID: 9391679
[TBL] [Abstract][Full Text] [Related]
20. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
Sparreboom A; van Zuylen L; Brouwer E; Loos WJ; de Bruijn P; Gelderblom H; Pillay M; Nooter K; Stoter G; Verweij J
Cancer Res; 1999 Apr; 59(7):1454-7. PubMed ID: 10197613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
